But JNJ-75276617 still has much to prove.

Blueprint looks to a next-gen Ayvakit, while Cogent challenges with a molecule acquired from Daiichi Sankyo.

Merck sees clinical setbacks in Keylynk-008, Leap-001 and Keyvibe-002.

Arvinas’s SERD appears to edge out Olema’s, but what’s the best CDK4/6 inhibitor for a phase 3 combination?

The company hopes that new edits could solve the relapse problem with allogeneic Car-Ts.

With inavolisib’s pivotal front-line win Roche reckons it can knock out Novartis’s Piqray.